FDA Grants Regular Approval to TRODELVY® for Advanced Triple Negative Breast Cancer
Prostate Cancer Risk Associated with Familial and Hereditary Cancer Syndromes
Radiation Therapy for Small-Cell Lung Cancer: ASCO Guideline Endorsement of an ASTRO Guideline
FDA Approves SARCLISA® Combination for Relapsed or Refractory Myeloma
FDA Approves Anti-BCMA CAR T-Cell Therapy for Relapsed or Refractory Multiple Myeloma
FDA Approves First Line KEYTRUDA® in Combination with Chemotherapy for Esophageal or Gastroesophageal Carcinoma
Advances in Triple Negative Breast Cancer
Therapy for Stage IV Non–Small-Cell Lung Cancer with Driver Alterations: ASCO and OH (CCO) Joint Guideline Update
FDA Approves TheraSphere Y-90 Glass Microspheres for Hepatocellular Carcinoma
Sugar-Sweetened Beverages May Increase Breast Cancer Mortality
FDA Approves PEPAXTO® for Relapsed or Refractory Multiple Myeloma
Worse Outcomes from COVID-19 Infection in Lymphoma Patients Treated with Anti-CD20 Monoclonal Antibodies
FDA Approves LORBRENA® for Advanced ALK-Positive Lung Cancer
Role of Aspirin in Colorectal Cancer Prevention and Mortality
PADCEV® Prolongs Overall Survival in Metastatic Urothelial Carcinoma
MARGENZA® Superior to Trastuzumab in Heavily Pretreated HER2-Positive Breast cancer
2021 ASCO GU Cancers Symposium: Apalutamide and Abiraterone plus Prednisone Improves PFS in Chemo-Naive mCRPC Patients
Advances with First-Line Dual Immunotherapies in Metastatic Non-Small Cell Lung Cancer
ASH 2021 Guidelines for Management of VTE in Patients with Cancer
FDA Approves LIBTAYO® for Advanced Basal Cell Carcinoma
Bottom Ad
Advertisement
Subscribe
